Seegene, Selventa Partner on MDx Development for 'Underserved Markets' | GenomeWeb

NEW YORK (GenomeWeb News) – Seegene and Selventa have entered into a collaborative agreement to develop molecular diagnostic products for "underserved markets" including autoimmune disease, cancer, and infectious diseases, the companies said today.

Under the partnership, the companies will combine Selventa's Systems Diagnostics "multi-omic analytics" platform with Seegene's qTOCE and DPO multiplex PCR chemistries to develop new molecular diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.